A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumours.

Trial Profile

A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumours.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs DS 2248 (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 02 Mar 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 18 Mar 2011 Additional lead trial investigator LoRusso Patricia identified as reported by Barbara Ann Karmanos Cancer Institute record.
    • 18 Mar 2011 New source identified and integrated (Barbara Ann Karmanos Cancer Institute, 2010-155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top